TL;DR
This paper introduces a novel two-drug combination therapy, "2iHDR," that significantly enhances the precision and efficiency of CRISPR-Cas9 genome editing. By simultaneously inhibiting DNA-PK and Polϴ, key enzymes involved in DNA repair, the researchers achieve up to 80% precise gene integration while drastically reducing unwanted mutations and off-target edits, paving the way for more reliable gene therapies.
What Problem Does This Paper Address?
CRISPR-Cas9 gene editing holds immense promise for treating genetic diseases, but its clinical application is hampered by two major limitations: low efficiency of precise DNA integration and the generation of unwanted mutations. These issues stem from the cell's natural DNA repair mechanisms, primarily Non-Homologous End Joining (NHEJ) and Microhomology-Mediated End Joining (MMEJ), which often lead to insertions and deletions (InDels) instead of the desired Homology-Directed Repair (HDR) for precise edits. This paper aims to overcome these limitations by developing a strategy to bias DNA repair towards HDR and minimize error-prone repair pathways.
Methods
The researchers employed a multi-pronged approach:
- High-Throughput Screening (HTS): They screened a library of over 20,000 small molecules using a "Traffic Light Reporter" (TLR) system in HEK293 cells. This system quantifies DNA repair outcomes by measuring the restoration of eGFP (indicating HDR) or the activation of DsRed (indicating NHEJ) after a Cas9-induced double-strand break.
- Knock-In Sequencing (KI-Seq): A novel NGS-based pipeline was developed to analyze DNA repair outcomes at Cas9-induced double-strand breaks. KI-Seq assigns InDel profiles to specific repair pathways (NHEJ, MMEJ, HDR-KI, NHEJ-KI, etc.), providing a detailed understanding of editing events.
- Pharmacological Inhibition: Based on HTS results, they identified and tested DNA-PK inhibitors (like AZD7648) and Polϴ inhibitors (like PolQi1 and PolQi2).
- Cell Line and Primary Cell Models: Experiments were conducted across various cell lines (HEK293T, Jurkat, HepG2) and primary cells (human CD4+ T cells, hepatocytes, iPSCs) to assess the broad applicability of their findings.
- Various Donor Templates: The study utilized different types of DNA donor templates (ssDNA, dsDNA) and integration strategies to evaluate the effectiveness of their approach.
- Advanced Sequencing Techniques: ddPCR and long-read sequencing were used to analyze large deletions, translocations, and off-target edits.
Datasets
- Screening Library: A library of 20,548 small molecules was used for the high-throughput screen.
- Genomic DNA from Edited Cells: DNA was extracted from various cell lines and primary cells after CRISPR-Cas9 editing experiments for analysis.
- Publicly Available Data: Next-generation sequencing data is available in the NCBI Sequence Read Archive database (SRA) under BioProject accession code PRJNA907774.
Key Insights and Ideas
- DNA-PK Inhibition is Key for HDR: The screening identified DNA-dependent protein kinase (DNA-PK) inhibitors as potent enhancers of HDR and reducers of NHEJ. This suggests a critical role for DNA-PK in directing repair pathway choice.
- MMEJ Inhibition Further Boosts Precision: While DNA-PK inhibition improved HDR, MMEJ-mediated deletions persisted. Inhibiting DNA Polymerase Theta (Polϴ), a key enzyme in MMEJ, further refined the editing outcome.
- The Power of Combination (2iHDR): The simultaneous inhibition of DNA-PK and Polϴ (dubbed "2iHDR") proved to be a synergistic strategy, dramatically increasing precise integration efficiency and nearly eliminating InDels.
- Broad Applicability: The 2iHDR strategy demonstrated effectiveness across a wide range of cell types, including primary cells, and with different donor templates and genomic loci.
- Reduced Off-Target Effects: Beyond improving on-target editing, 2iHDR also significantly reduced Cas9-associated off-target mutations and translocations, enhancing the safety profile of genome editing.
Key Results
- Up to 80% Precise Integration: The 2iHDR treatment achieved templated insertion efficiencies of up to 80% in some cases.
- Near-Elimination of InDels: The combination therapy resulted in nearly no formation of undesired Insertion-Deletions (InDels).
- Significant HDR Enhancement: AZD7648 (a DNA-PK inhibitor) treatment increased HDR-mediated knock-in efficiencies by up to 12.6-fold in primary human CD4+ T cells.
- Reduced NHEJ and MMEJ: 2iHDR treatment consistently reduced NHEJ-dependent InDels by up to 13.7-fold and also decreased large deletions associated with MMEJ.
- Improved Integration in Primary Cells: In primary human CD4+ T cells, 2iHDR treatment showed a 3.5- to 8.6-fold increase in editing efficiency compared to untreated controls.
- Reduced Off-Target Mutations: The study demonstrated a significant decrease in off-target editing when using 2iHDR.
Limitations and Future Work
- Shortcomings of KI-Seq: The authors acknowledge that KI-Seq's reliance on small amplicons limits its ability to investigate complex DNA rearrangements. Future work could involve integrating ddPCR and long-read sequencing to address this.
- Uncharacterized Side Effects: While 2iHDR showed promising results, the authors note that uncharacterized, undesirable side effects of simultaneous NHEJ/MMEJ inhibition cannot be entirely excluded. Further studies investigating the genome-wide impact of this inhibition on spontaneously occurring DSBs are needed.
- Broad Applicability and Clinical Translation: The study highlights the broad applicability of 2iHDR across various cell types and donor templates, suggesting its potential for accelerating CRISPR-mediated KI for both research and clinical applications. The authors anticipate that this strategy will significantly improve performance over existing methods.
Summary updated